



IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Sandrine BUSSERET-MICHEL et al.

Application No.: 10/590,272

Filed: August 22, 2006

Docket No.: 129022

For: METHOD FOR DETECTING THE ACTIVATABLE FREE FORM OF PSA AND THE
USE THEREOF FOR DIAGNOSING BENIGN PATHOLOGIES OF THE PROSTATE
AND ADENOCARCINOMA OF THE PROSTATE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.

- ☒ 2. One or more reference cited herein was cited in the International Search Report. An English language version of the International Search Report is attached for the Examiner's information. See References 1-5, 18 and 19.
- ☒ 3. An English language Abstract of one or more non-English language reference is attached hereto. See References 1-3.

Respectfully submitted,


James A. Oliff
Registration No. 27,075

David R. Kemeny
Registration No. 57,241


JAO:DRK/kxs

Date: November 1, 2006

OLIFF & BERRIDGE, PLC
P.O. Box 19928
Alexandria, Virginia 22320
Telephone: (703) 836-6400

**DEPOSIT ACCOUNT USE
AUTHORIZATION**

Please grant any extension
necessary for entry;
Charge any fee due to our
Deposit Account No. 15-0461



Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 129022		APPLICATION NO. 10/590,272	
INFORMATION DISCLOSURE STATEMENT							
(Use several sheets if necessary)				APPLICANT(S) Sandrine BUSSET-MICHEL et al.			
				FILING DATE August 22, 2006		GROUP	
U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Date	Name			
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract	With English Translation	
	1	WO 1/77180 A1	10/18/2001		X		
	2	WO 00/02052	01/13/2000		X		
	3	WO 01/96876 A1	12/20/2001		X		
OTHER DOCUMENTS							
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)					
	4	Lilja, Hans, "Biology of Prostate-Specific Antigen", pgs. 27-33, <u>Urology</u> 62 (Supplement 5A), November 2003.					
	5	Michel, Sandrine et al., "Selective Recognition of Enzymatically Active Prostate-Specific Antigen (PSA) by Anti-PSA Monoclonal Antibodies", pgs. 225-235, <u>Journal of Molecular Recognition</u> , Vol. 18, 2005.					
	6	Wu, James T. et al., "Production of Milligram Concentrations of Free Prostate Specific Antigen (fPSA) from LNCaP Cell Culture: Difference Between fPSA From LNCaP Cell and Seminal Plasma", pgs. 6-13, <u>Journal of Clinical Laboratory Analysis</u> , Vol. 12, 1998.					
	7	Charrier, Jean-Philippe et al., "Differential Diagnosis of Prostate Cancer and Benign Prostate Hyperplasia Using Two-Dimensional Electrophoresis", pgs. 1861-1866, <u>Electrophoresis</u> , Vol. 22, 2001.					
	8	Michel, Sandrine et al., "Involvement of the C-Terminal End of the Prostate-Specific Antigen in a Conformational Epitope: Characterization by Proteolytic Degradation of Monoclonal Antibody-Bound Antigen and Mass Spectrometry", pgs. 406-413, <u>Journal of Molecular Recognition</u> , Vol. 14, 2001.					
	9	Chevalier, Jacques et al., "Biotin and Digoxigenin as Labels for Light and Electron Microscopy In Situ Hybridization Probes: Where Do We Stand?", pgs. 481-491, <u>The Journal of Histochemistry & Cytochemistry</u> , Vol. 45(4), 1997.					
	10	Nagasaki, Hiroshi et al., "Epitope Analysis of a Prostate-Specific Antigen (PSA) C-Terminal-Specific Monoclonal Antibody and New Aspects for the Discrepancy Between Equimolar and Skewed PSA Assays, pgs. 486-496, <u>Clinical Chemistry</u> , Vol. 45(4), 1999.					
	11	Lein, M. et al., "Relation of Free PSA/Total PSA in Serum for Differentiating Between Patients with Prostatic Cancer and Benign Hyperplasia of the Prostate: Which Cutoff Should Be Used?", pgs. 45-49, <u>Cancer Investigation</u> , Vol. 16(1), 1998.					
	12	Christensson, Anders et al., "Enzymatic Activity of Prostate-Specific Antigen and its Reactions With Extracellular Serine Proteinase Inhibitors", pgs. 755-763, <u>European Journal of Biochemistry</u> , 1990.					
	13	Catalona, William J. et al., "Prostate Cancer Detection In Men With Serum PSA Concentrations of 2.6 to 4.0 ng/mL and Benign Prostate Examination--Enhancement of Specificity With Free PSA Measurements", pgs. 1452-1455, <u>JAMA</u> , Vol. 277, No. 18, May 14, 1997.					
	14	McGee, Robert S. et al., "Human Seminal Vesicle-Specific Antigen Is a Substrate for Prostate-Specific Antigen (or P-30)", pgs. 499-510, <u>Biology of Reproduction</u> , Vol. 39, 1988.					

	15	Lilja, Hans, "A Kallikren-like Serine Protease in Prostatic Fluid Cleaves the Predominant Seminal Vesicle Protein", pgs. 1899-1903, <u>The Journal of Clinical Investigation</u> , Vol. 76, November 1985.
	16	Lundwall, Ake et al., "Molecular Cloning of Human Prostate Specific Antigen cDNA", pgs. 317-322. <u>Federation of European Biochemical Societies</u> , Vol. 214, No. 2, April 1987.
	17	Herrala, Annakaisa et al., "Androgen Sensitive Human Prostate Cancer Cells, LNCaP, Produce Both N-Terminally Mature and Truncated Prostate-Specific Antigen Isoforms", pgs. 329-335, <u>European Journal of Biochemistry</u> , Number 255, 1988.
	18	Corey, Eva et al., "LNCaP Produces Both Putative Zymogen and Inactive, Free Form of Prostate-Specific Antigen", pgs.135-143, <u>The Prostate</u> , Vol. 35, 1998.
	19	Michel, Sandrine et al., "Anti-Free Prostate-Specific Antigen Monoclonal Antibody Epitopes Defined By Mimotopes and Molecular Modeling", pgs. 638-650, <u>Clinical Chemistry</u> , Vol. 45:5, 1999.
EXAMINER		DATE CONSIDERED
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Date: November 1, 2006